Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 132

1.

Engineered Cardiac Tissues Generated in the Biowire™ II: A Platform for Human-Based Drug Discovery.

Feric NT, Pallotta I, Singh R, Bogdanowicz DR, Gustilo M, Chaudhary K, Willette RN, Chendrimada T, Xu X, Graziano MP, Aschar-Sobbi R.

Toxicol Sci. 2019 Aug 6. pii: kfz168. doi: 10.1093/toxsci/kfz168. [Epub ahead of print]

PMID:
31385592
2.

CXA-10, a Nitrated Fatty Acid, Is Renoprotective in Deoxycorticosterone Acetate-Salt Nephropathy.

Arbeeny CM, Ling H, Smith MM, O'Brien S, Wawersik S, Ledbetter SR, McAlexander A, Schopfer FJ, Willette RN, Jorkasky DK.

J Pharmacol Exp Ther. 2019 Jun;369(3):503-510. doi: 10.1124/jpet.118.254755. Epub 2019 Mar 20.

PMID:
30894457
3.

Inhibition of Apoptosis Signal-Regulating Kinase 1 Attenuates Myocyte Hypertrophy and Fibroblast Collagen Synthesis.

Yang W, Wang BH, Wang I, Huang L, Savira F, Kompa A, Jucker BM, Willette RN, Kelly D, Krum H, Li Z, Fu Q.

Heart Lung Circ. 2019 Mar;28(3):495-504. doi: 10.1016/j.hlc.2017.12.001. Epub 2017 Dec 14.

PMID:
29277546
4.

Apoptosis signal-regulating kinase 1 inhibition attenuates cardiac hypertrophy and cardiorenal fibrosis induced by uremic toxins: Implications for cardiorenal syndrome.

Savira F, Cao L, Wang I, Yang W, Huang K, Hua Y, Jucker BM, Willette RN, Huang L, Krum H, Li Z, Fu Q, Wang BH.

PLoS One. 2017 Nov 6;12(11):e0187459. doi: 10.1371/journal.pone.0187459. eCollection 2017.

5.

The prolyl 4-hydroxylase inhibitor GSK360A decreases post-stroke brain injury and sensory, motor, and cognitive behavioral deficits.

Zhou J, Li J, Rosenbaum DM, Zhuang J, Poon C, Qin P, Rivera K, Lepore J, Willette RN, Hu E, Barone FC.

PLoS One. 2017 Sep 7;12(9):e0184049. doi: 10.1371/journal.pone.0184049. eCollection 2017.

6.

PROPERTIES OF THE TRPV4 AGONIST GSK1016790A AND the TRPV4 ANTAGONIST GSK2193874.

Thorneloe KS, Cheung M, Holt DA, Willette RN.

Physiol Rev. 2017 Oct 1;97(4):1231-1232. doi: 10.1152/physrev.00019.2017. No abstract available.

7.

Discovery of GSK2193874: An Orally Active, Potent, and Selective Blocker of Transient Receptor Potential Vanilloid 4.

Cheung M, Bao W, Behm DJ, Brooks CA, Bury MJ, Dowdell SE, Eidam HS, Fox RM, Goodman KB, Holt DA, Lee D, Roethke TJ, Willette RN, Xu X, Ye G, Thorneloe KS.

ACS Med Chem Lett. 2017 Mar 20;8(5):549-554. doi: 10.1021/acsmedchemlett.7b00094. eCollection 2017 May 11.

8.

Activation of the Amino Acid Response Pathway Blunts the Effects of Cardiac Stress.

Qin P, Arabacilar P, Bernard RE, Bao W, Olzinski AR, Guo Y, Lal H, Eisennagel SH, Platchek MC, Xie W, Del Rosario J, Nayal M, Lu Q, Roethke T, Schnackenberg CG, Wright F, Quaile MP, Halsey WS, Hughes AM, Sathe GM, Livi GP, Kirkpatrick RB, Qu XA, Rajpal DK, Faelth Savitski M, Bantscheff M, Joberty G, Bergamini G, Force TL, Gatto GJ Jr, Hu E, Willette RN.

J Am Heart Assoc. 2017 May 9;6(5). pii: e004453. doi: 10.1161/JAHA.116.004453.

9.

Toward improved myocardial maturity in an organ-on-chip platform with immature cardiac myocytes.

Sheehy SP, Grosberg A, Qin P, Behm DJ, Ferrier JP, Eagleson MA, Nesmith AP, Krull D, Falls JG, Campbell PH, McCain ML, Willette RN, Hu E, Parker KK.

Exp Biol Med (Maywood). 2017 Nov;242(17):1643-1656. doi: 10.1177/1535370217701006. Epub 2017 Mar 26.

10.

Cardioprotection Resulting from Glucagon-Like Peptide-1 Administration Involves Shifting Metabolic Substrate Utilization to Increase Energy Efficiency in the Rat Heart.

Aravindhan K, Bao W, Harpel MR, Willette RN, Lepore JJ, Jucker BM.

PLoS One. 2015 Jun 22;10(6):e0130894. doi: 10.1371/journal.pone.0130894. eCollection 2015.

11.

TRPV4 inhibition counteracts edema and inflammation and improves pulmonary function and oxygen saturation in chemically induced acute lung injury.

Balakrishna S, Song W, Achanta S, Doran SF, Liu B, Kaelberer MM, Yu Z, Sui A, Cheung M, Leishman E, Eidam HS, Ye G, Willette RN, Thorneloe KS, Bradshaw HB, Matalon S, Jordt SE.

Am J Physiol Lung Cell Mol Physiol. 2014 Jul 15;307(2):L158-72. doi: 10.1152/ajplung.00065.2014. Epub 2014 May 16.

12.

Combined TRPC3 and TRPC6 blockade by selective small-molecule or genetic deletion inhibits pathological cardiac hypertrophy.

Seo K, Rainer PP, Shalkey Hahn V, Lee DI, Jo SH, Andersen A, Liu T, Xu X, Willette RN, Lepore JJ, Marino JP Jr, Birnbaumer L, Schnackenberg CG, Kass DA.

Proc Natl Acad Sci U S A. 2014 Jan 28;111(4):1551-6. doi: 10.1073/pnas.1308963111. Epub 2014 Jan 22. Erratum in: Proc Natl Acad Sci U S A. 2014 Apr 22;111(16):6115.

13.

Cardioprotection by systemic dosing of thymosin beta four following ischemic myocardial injury.

Bao W, Ballard VL, Needle S, Hoang B, Lenhard SC, Tunstead JR, Jucker BM, Willette RN, Pipes GT.

Front Pharmacol. 2013 Nov 29;4:149. doi: 10.3389/fphar.2013.00149. eCollection 2013.

14.

Novel fusion of GLP-1 with a domain antibody to serum albumin prolongs protection against myocardial ischemia/reperfusion injury in the rat.

Bao W, Holt LJ, Prince RD, Jones GX, Aravindhan K, Szapacs M, Barbour AM, Jolivette LJ, Lepore JJ, Willette RN, DeAngelis E, Jucker BM.

Cardiovasc Diabetol. 2013 Oct 14;12:148. doi: 10.1186/1475-2840-12-148.

15.

The discovery of potent blockers of the canonical transient receptor channels, TRPC3 and TRPC6, based on an anilino-thiazole pharmacophore.

Washburn DG, Holt DA, Dodson J, McAtee JJ, Terrell LR, Barton L, Manns S, Waszkiewicz A, Pritchard C, Gillie DJ, Morrow DM, Davenport EA, Lozinskaya IM, Guss J, Basilla JB, Negron LK, Klein M, Willette RN, Fries RE, Jensen TC, Xu X, Schnackenberg CG, Marino JP Jr.

Bioorg Med Chem Lett. 2013 Sep 1;23(17):4979-84. doi: 10.1016/j.bmcl.2013.06.047. Epub 2013 Jun 26.

PMID:
23886683
16.

Human-induced pluripotent stem cell-derived cardiomyocytes exhibit temporal changes in phenotype.

Ivashchenko CY, Pipes GC, Lozinskaya IM, Lin Z, Xiaoping X, Needle S, Grygielko ET, Hu E, Toomey JR, Lepore JJ, Willette RN.

Am J Physiol Heart Circ Physiol. 2013 Sep 15;305(6):H913-22. doi: 10.1152/ajpheart.00819.2012. Epub 2013 Jul 5.

17.

Chronic inhibition of 11 β -hydroxysteroid dehydrogenase type 1 activity decreases hypertension, insulin resistance, and hypertriglyceridemia in metabolic syndrome.

Schnackenberg CG, Costell MH, Krosky DJ, Cui J, Wu CW, Hong VS, Harpel MR, Willette RN, Yue TL.

Biomed Res Int. 2013;2013:427640. doi: 10.1155/2013/427640. Epub 2013 Mar 18.

18.

Soluble epoxide hydrolase inhibition does not prevent cardiac remodeling and dysfunction after aortic constriction in rats and mice.

Morgan LA, Olzinski AR, Upson JJ, Zhao S, Wang T, Eisennagel SH, Hoang B, Tunstead JR, Marino JP Jr, Willette RN, Jucker BM, Behm DJ.

J Cardiovasc Pharmacol. 2013 Apr;61(4):291-301. doi: 10.1097/FJC.0b013e31827fe59c.

PMID:
23232840
19.

An orally active TRPV4 channel blocker prevents and resolves pulmonary edema induced by heart failure.

Thorneloe KS, Cheung M, Bao W, Alsaid H, Lenhard S, Jian MY, Costell M, Maniscalco-Hauk K, Krawiec JA, Olzinski A, Gordon E, Lozinskaya I, Elefante L, Qin P, Matasic DS, James C, Tunstead J, Donovan B, Kallal L, Waszkiewicz A, Vaidya K, Davenport EA, Larkin J, Burgert M, Casillas LN, Marquis RW, Ye G, Eidam HS, Goodman KB, Toomey JR, Roethke TJ, Jucker BM, Schnackenberg CG, Townsley MI, Lepore JJ, Willette RN.

Sci Transl Med. 2012 Nov 7;4(159):159ra148. doi: 10.1126/scitranslmed.3004276.

20.

Unrestrained p38 MAPK activation in Dusp1/4 double-null mice induces cardiomyopathy.

Auger-Messier M, Accornero F, Goonasekera SA, Bueno OF, Lorenz JN, van Berlo JH, Willette RN, Molkentin JD.

Circ Res. 2013 Jan 4;112(1):48-56. doi: 10.1161/CIRCRESAHA.112.272963. Epub 2012 Sep 19. Erratum in: Circ Res. 2013 Feb 1;112(3):e32.

21.

Effects of p38 mitogen-activated protein kinase inhibition on vascular and systemic inflammation in patients with atherosclerosis.

Elkhawad M, Rudd JH, Sarov-Blat L, Cai G, Wells R, Davies LC, Collier DJ, Marber MS, Choudhury RP, Fayad ZA, Tawakol A, Gleeson FV, Lepore JJ, Davis B, Willette RN, Wilkinson IB, Sprecher DL, Cheriyan J.

JACC Cardiovasc Imaging. 2012 Sep;5(9):911-22. doi: 10.1016/j.jcmg.2012.02.016.

22.

Comparison of soluble guanylate cyclase stimulators and activators in models of cardiovascular disease associated with oxidative stress.

Costell MH, Ancellin N, Bernard RE, Zhao S, Upson JJ, Morgan LA, Maniscalco K, Olzinski AR, Ballard VL, Herry K, Grondin P, Dodic N, Mirguet O, Bouillot A, Gellibert F, Coatney RW, Lepore JJ, Jucker BM, Jolivette LJ, Willette RN, Schnackenberg CG, Behm DJ.

Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012.

23.

Albiglutide, a long lasting glucagon-like peptide-1 analog, protects the rat heart against ischemia/reperfusion injury: evidence for improving cardiac metabolic efficiency.

Bao W, Aravindhan K, Alsaid H, Chendrimada T, Szapacs M, Citerone DR, Harpel MR, Willette RN, Lepore JJ, Jucker BM.

PLoS One. 2011;6(8):e23570. doi: 10.1371/journal.pone.0023570. Epub 2011 Aug 26.

24.

Serial MRI characterization of the functional and morphological changes in mouse lung in response to cardiac remodeling following myocardial infarction.

Alsaid H, Bao W, Rambo MV, Logan GA, Figueroa DJ, Lenhard SC, Kotzer CJ, Burgert ME, Willette RN, Ferrari VA, Jucker BM.

Magn Reson Med. 2012 Jan;67(1):191-200. doi: 10.1002/mrm.22973. Epub 2011 Jun 10.

25.

Inhibition of p38 mitogen-activated protein kinase improves nitric oxide-mediated vasodilatation and reduces inflammation in hypercholesterolemia.

Cheriyan J, Webb AJ, Sarov-Blat L, Elkhawad M, Wallace SM, Mäki-Petäjä KM, Collier DJ, Morgan J, Fang Z, Willette RN, Lepore JJ, Cockcroft JR, Sprecher DL, Wilkinson IB.

Circulation. 2011 Feb 8;123(5):515-23. doi: 10.1161/CIRCULATIONAHA.110.971986. Epub 2011 Jan 24.

PMID:
21262998
26.

GSK1562590, a slowly dissociating urotensin-II receptor antagonist, exhibits prolonged pharmacodynamic activity ex vivo.

Behm DJ, Aiyar NV, Olzinski AR, McAtee JJ, Hilfiker MA, Dodson JW, Dowdell SE, Wang GZ, Goodman KB, Sehon CA, Harpel MR, Willette RN, Neeb MJ, Leach CA, Douglas SA.

Br J Pharmacol. 2010 Sep;161(1):207-28. doi: 10.1111/j.1476-5381.2010.00889.x.

27.

Chronic inhibition of hypoxia-inducible factor prolyl 4-hydroxylase improves ventricular performance, remodeling, and vascularity after myocardial infarction in the rat.

Bao W, Qin P, Needle S, Erickson-Miller CL, Duffy KJ, Ariazi JL, Zhao S, Olzinski AR, Behm DJ, Pipes GC, Jucker BM, Hu E, Lepore JJ, Willette RN.

J Cardiovasc Pharmacol. 2010 Aug;56(2):147-55. doi: 10.1097/FJC.0b013e3181e2bfef.

PMID:
20714241
28.

Inhibition of p38 mitogen-activated protein kinase reduces inflammation after coronary vascular injury in humans.

Sarov-Blat L, Morgan JM, Fernandez P, James R, Fang Z, Hurle MR, Baidoo C, Willette RN, Lepore JJ, Jensen SE, Sprecher DL.

Arterioscler Thromb Vasc Biol. 2010 Nov;30(11):2256-63. doi: 10.1161/ATVBAHA.110.209205. Epub 2010 Aug 5.

PMID:
20689074
29.

Pharmacological inhibition of C-C chemokine receptor 2 decreases macrophage infiltration in the aortic root of the human C-C chemokine receptor 2/apolipoprotein E-/- mouse: magnetic resonance imaging assessment.

Olzinski AR, Turner GH, Bernard RE, Karr H, Cornejo CA, Aravindhan K, Hoang B, Ringenberg MA, Qin P, Goodman KB, Willette RN, Macphee CH, Jucker BM, Sehon CA, Gough PJ.

Arterioscler Thromb Vasc Biol. 2010 Feb;30(2):253-9. doi: 10.1161/ATVBAHA.109.198812. Epub 2009 Dec 3. Erratum in: Arterioscler Thromb Vasc Biol. 2010 Sep;30(9):e170.

PMID:
19965779
30.

In vivo serial assessment of aortic aneurysm formation in apolipoprotein E-deficient mice via MRI.

Turner GH, Olzinski AR, Bernard RE, Aravindhan K, Karr HW, Mirabile RC, Willette RN, Gough PJ, Jucker BM.

Circ Cardiovasc Imaging. 2008 Nov;1(3):220-6. doi: 10.1161/CIRCIMAGING.108.787358. Epub 2008 Sep 17.

PMID:
19808546
31.

Assessment of macrophage infiltration in a murine model of abdominal aortic aneurysm.

Turner GH, Olzinski AR, Bernard RE, Aravindhan K, Boyle RJ, Newman MJ, Gardner SD, Willette RN, Gough PJ, Jucker BM.

J Magn Reson Imaging. 2009 Aug;30(2):455-60. doi: 10.1002/jmri.21843.

PMID:
19629967
32.

Differential effects of p38 mitogen-activated protein kinase and cyclooxygenase 2 inhibitors in a model of cardiovascular disease.

Willette RN, Eybye ME, Olzinski AR, Behm DJ, Aiyar N, Maniscalco K, Bentley RG, Coatney RW, Zhao S, Westfall TD, Doe CP.

J Pharmacol Exp Ther. 2009 Sep;330(3):964-70. doi: 10.1124/jpet.109.154443. Epub 2009 Jun 25.

PMID:
19556450
33.

1-[1-Hexyl-6-(methyloxy)-1H-indazol-3-yl]-2-methyl-1-propanone, a potent and highly selective small molecule blocker of the large-conductance voltage-gated and calcium-dependent K+ channel.

Zeng H, Gordon E, Lin Z, Lozinskaya IM, Willette RN, Xu X.

J Pharmacol Exp Ther. 2008 Oct;327(1):168-77. doi: 10.1124/jpet.108.139733. Epub 2008 Jun 30.

PMID:
18591221
34.

Systemic activation of the transient receptor potential vanilloid subtype 4 channel causes endothelial failure and circulatory collapse: Part 2.

Willette RN, Bao W, Nerurkar S, Yue TL, Doe CP, Stankus G, Turner GH, Ju H, Thomas H, Fishman CE, Sulpizio A, Behm DJ, Hoffman S, Lin Z, Lozinskaya I, Casillas LN, Lin M, Trout RE, Votta BJ, Thorneloe K, Lashinger ES, Figueroa DJ, Marquis R, Xu X.

J Pharmacol Exp Ther. 2008 Aug;326(2):443-52. doi: 10.1124/jpet.107.134551. Epub 2008 May 22. Erratum in: J Pharmacol Exp Ther. 2011 Jul;338(1):408-9.

PMID:
18499744
35.

In vivo activation of peroxisome proliferator-activated receptor-delta protects the heart from ischemia/reperfusion injury in Zucker fatty rats.

Yue TL, Nerurkar SS, Bao W, Jucker BM, Sarov-Blat L, Steplewski K, Ohlstein EH, Willette RN.

J Pharmacol Exp Ther. 2008 May;325(2):466-74. doi: 10.1124/jpet.107.135327. Epub 2008 Feb 20.

PMID:
18287212
36.

p38 MAPK inhibition reduces aortic ultrasmall superparamagnetic iron oxide uptake in a mouse model of atherosclerosis: MRI assessment.

Morris JB, Olzinski AR, Bernard RE, Aravindhan K, Mirabile RC, Boyce R, Willette RN, Jucker BM.

Arterioscler Thromb Vasc Biol. 2008 Feb;28(2):265-71. Epub 2007 Dec 27.

PMID:
18162612
37.

2-[2-(3,4-dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-nicotinic acid (PD-307243) causes instantaneous current through human ether-a-go-go-related gene potassium channels.

Gordon E, Lozinskaya IM, Lin Z, Semus SF, Blaney FE, Willette RN, Xu X.

Mol Pharmacol. 2008 Mar;73(3):639-51. Epub 2007 Nov 27.

PMID:
18042732
38.

PPARdelta activation normalizes cardiac substrate metabolism and reduces right ventricular hypertrophy in congestive heart failure.

Jucker BM, Doe CP, Schnackenberg CG, Olzinski AR, Maniscalco K, Williams C, Hu TC, Lenhard SC, Costell M, Bernard R, Sarov-Blat L, Steplewski K, Willette RN.

J Cardiovasc Pharmacol. 2007 Jul;50(1):25-34.

PMID:
17666912
39.

Effects of p38 MAPK Inhibitor on angiotensin II-dependent hypertension, organ damage, and superoxide anion production.

Bao W, Behm DJ, Nerurkar SS, Ao Z, Bentley R, Mirabile RC, Johns DG, Woods TN, Doe CP, Coatney RW, Ohlstein JF, Douglas SA, Willette RN, Yue TL.

J Cardiovasc Pharmacol. 2007 Jun;49(6):362-8.

PMID:
17577100
40.

Carvedilol prevents and reverses hypertrophy-induced cardiac dysfunction.

Barone FC, Willette RN, Nelson AH, Ohlstein EH, Brooks DP, Coatney RW.

Pharmacology. 2007;80(2-3):166-76. Epub 2007 Jun 4.

PMID:
17551266
41.

P38 MAPK inhibitors suppress biomarkers of hypertension end-organ damage, osteopontin and plasminogen activator inhibitor-1.

Nerurkar SS, Olzinski AR, Frazier KS, Mirabile RC, O'Brien SP, Jing J, Rajagopalan D, Yue TL, Willette RN.

Biomarkers. 2007 Jan-Feb;12(1):87-112.

PMID:
17438656
42.

Acetic acid opens large-conductance Ca2+-activated K+ channels in guinea pig detrusor smooth muscle cells.

Ghatta S, Lozinskaya I, Lin Z, Gordon E, Willette RN, Brooks DP, Xu X.

Eur J Pharmacol. 2007 Jun 1;563(1-3):203-8. Epub 2007 Feb 27.

PMID:
17382925
43.

Mallotoxin is a novel human ether-a-go-go-related gene (hERG) potassium channel activator.

Zeng H, Lozinskaya IM, Lin Z, Willette RN, Brooks DP, Xu X.

J Pharmacol Exp Ther. 2006 Nov;319(2):957-62. Epub 2006 Aug 23.

PMID:
16928897
44.

Lysophosphatidylcholine induces inflammatory activation of human coronary artery smooth muscle cells.

Aiyar N, Disa J, Ao Z, Ju H, Nerurkar S, Willette RN, Macphee CH, Johns DG, Douglas SA.

Mol Cell Biochem. 2007 Jan;295(1-2):113-20. Epub 2006 Aug 8.

PMID:
16896535
45.

Assessing the effects of LXR agonists on cellular cholesterol handling: a stable isotope tracer study.

Aravindhan K, Webb CL, Jaye M, Ghosh A, Willette RN, DiNardo NJ, Jucker BM.

J Lipid Res. 2006 Jun;47(6):1250-60. Epub 2006 Mar 27.

46.

SB-267268, a nonpeptidic antagonist of alpha(v)beta3 and alpha(v)beta5 integrins, reduces angiogenesis and VEGF expression in a mouse model of retinopathy of prematurity.

Wilkinson-Berka JL, Jones D, Taylor G, Jaworski K, Kelly DJ, Ludbrook SB, Willette RN, Kumar S, Gilbert RE.

Invest Ophthalmol Vis Sci. 2006 Apr;47(4):1600-5.

PMID:
16565398
47.

The peptidic urotensin-II receptor ligand GSK248451 possesses less intrinsic activity than the low-efficacy partial agonists SB-710411 and urantide in native mammalian tissues and recombinant cell systems.

Behm DJ, Stankus G, Doe CP, Willette RN, Sarau HM, Foley JJ, Schmidt DB, Nuthulaganti P, Fornwald JA, Ames RS, Lambert DG, Calo' G, Camarda V, Aiyar NV, Douglas SA.

Br J Pharmacol. 2006 May;148(2):173-90.

48.

Lipopolysaccharide (LPS) contamination plays the real role in C-reactive protein-induced IL-6 secretion from human endothelial cells in vitro.

Nerurkar SS, McDevitt PJ, Scott GF, Johanson KO, Willette RN, Yue TL.

Arterioscler Thromb Vasc Biol. 2005 Sep;25(9):e136. No abstract available.

PMID:
16127022
49.

Synthetic LXR agonists increase LDL in CETP species.

Groot PH, Pearce NJ, Yates JW, Stocker C, Sauermelch C, Doe CP, Willette RN, Olzinski A, Peters T, d'Epagnier D, Morasco KO, Krawiec JA, Webb CL, Aravindhan K, Jucker B, Burgert M, Ma C, Marino JP, Collins JL, Macphee CH, Thompson SK, Jaye M.

J Lipid Res. 2005 Oct;46(10):2182-91. Epub 2005 Jul 16.

50.

Quantitative analysis of orphan G protein-coupled receptor mRNAs by TaqMan Real-Time PCR: G2A and GPR4 lysophospholipid receptor expression in leukocytes and in a rat myocardial infarction-heart failure model.

Douglas SA, Ao Z, Johns DG, Maniscalco K, Willette RN, Sarov-Blat L, Cogswell JP, Seepersaud S, Murdock P, Steplewski KM, Patel L.

Methods Mol Biol. 2005;306:27-49. No abstract available.

PMID:
15867463

Supplemental Content

Loading ...
Support Center